Introduction
Inwardly rectifier potassium (Kir) channels play fundamental roles in the regulation of membrane potential and potassium (K + ) secretion in numerous excitable and non-excitable tissues (Hibino et al., 2010) . Kir channels are tetramers, with each subunit possessing two membrane-spanning domains, a re-entrant pore loop, and cytoplasmic domain comprised of the intracellular amino-and carboxyl-termini (Kuo et al., 2003; Lee et al., 2016; Nishida et al., 2007; Tao et al., 2009) . Kir channels are gated in a voltage-dependent manner by intracellular polyamines and magnesium ions that work by occluding the channel pore at membrane potentials more positive than the Nernst equilibrium potential for K + (Ficker et al., 1994; Lopatin et al., 1994) . This voltage-dependent pore block at more positive potentials gives rise to the nonlinear current-voltage relationship, or inward rectification, which defines the channel family. The strength of rectification is determined in part by the presence or absence of negatively charged residues (e.g. aspartate [D] or glutamate [E] ) in the membrane-spanning pore that coordinate the interaction of pore-blocking molecules (Lu and MacKinnon, 1994; Stanfield et al., 1994 ; Wible
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Kir1.1 and Kir7.1 homology modeling
The comparative models of Kir1.1 (UniProt ID P48048) and Kir7.1 (UniProt ID O60928)
were generated with Modeller v.9.9 (Sali and Blundell, 1993) based on the 3.11 Å resolution crystal structure of Kir2.2 (PDB ID 3JYC) (Tao et al., 2009) . Loop sampling and model refinement was performed using Rosetta 3.3 (Wang et al., 2007) . The VU590 inhibitor was docked into the Kir7.1 model using MOE, the Molecular Operating Environment (Chemical Computing Group, Montreal, Quebec, Canada) . Out of 1000 models built, the best scoring (lowest potential energy) model of each channel was used for docking VU590.
VU590 docking
The three-dimensional structure of VU590 was built using MOE, and 100 low-energy conformations were generated using BCL (Kothiwale et al., 2015) to represent the flexibility of the ligand. In-silico docking was performed using RosettaScripts version 3.7 (Bender et al., 2016) , starting from an initial placement in the pore cavity near putative binding site residues identified with site-directed mutagenesis. The docking was performed in 500 independent Monte
Carlo trajectories for each channel, permitting side-chain flexibility and minimization of both the ligand and protein coordinates. Docked poses were considered equivalent by accounting for the four-fold symmetry of the channels. Because strong convergence on a single docking solution was not observed, five of the top-ranked poses were selected to represent an ensemble of lowenergy binding modes to each protein.
Results
Mutation of Kir1.1-N171 augments VU590 sensitivity
Block of Kir1.1 by VU590 is voltage-dependent, suggesting the small-molecule binding site is located within the ion-conduction pathway (Lewis et al., 2009 )(Supplemental Fig. S1 ).
Mutagenesis experiments have demonstrated that asparagine 171 (N171) in the membranespanning pore (Fig. 1A) 6%; n=6) . No other pore-lining residues were found to be necessary for highaffinity block of Kir1.1 (Fig. 1D) .
VU590 is Kir7.1 pore blocker that interacts with E149, A150 and T153
To begin testing if VU590 is a pore blocker of Kir7.1, we first evaluated the voltagedependence of inhibition under normal (5 mM) and high (100 mM) extracellular K + conditions.
As shown in the current traces in Fig. 2A , B and mean ± SD data in Fig. 2C Given that a negatively charged residue at position 171 in Kir1.1 reduces block by VU590 (Fig. 1B) , we hypothesized that E149 at the equivalent position in Kir7.1 accounted for its reduced sensitivity to VU590. Unfortunately, mutation of E149 to asparagine (E149N) or
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This article has not been copyedited and formatted. The final version may differ from this version. glutamine (E149Q) produced non-functional channels that could not be studied in the wild type background. We therefore re-tested these mutations in the M125R background, which increases the unitary conductance of Kir7.1 (Doring et al., 1998; Krapivinsky et al., 1998) background (Kir7.1-L146V-M125R), I152 to methionine (Kir7.1-I152M), and mutation of glycine 154 to alanine (Kir7.1-G154A) had no effect on VU590 sensitivity. Whereas the A150S mutation reduced VU590 block by itself (5.4±7.6% at 10 µM VU590; n=5) and was synergistic with the E149Q mutation (inhibition of Kir7.1-E149Q-A150S-M125R by 10 µM VU590 =1.1±2.73%; n=6). Kir7.1-F156I and Kir7.1-V157L were non-functional in the wild type and M125R backgrounds (data not shown). However, we found that mutation of threonine 153 to cysteine (Kir7.1-T153C) led to a six-fold improvement in VU590 sensitivity (Figs. 3A, B, and 4A)(Kir7.1-WT IC 50 ~6.18 µM 95% CI:4.8 µM-7.9 µM n≥6 and Kir7.1-T153C IC 50 ~1.041 µM;
95% CI: 0.92 µM-1.17 µM n≥6), prompting us to explore the underlying mechanism in greater detail.
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Constrained polarity at Kir7.1-T153 creates a barrier for low-affinity pore blockers
The Kir7.1-T153C mutation retains polarity at this site, but reduces side chain bulk and hence rotamer flexibility. The enhanced block is not due to effects on the neighboring "glycine hinge" residue, G154, because the T153C mutation was still effective in the presence of the G154A mutation (Fig. 3A) (see Discussion). To determine if side chain polarity, bulk, or both contribute to the increased block of Kir7.1 by VU590, we first mutated Kir7.1-T153 to valine (Kir7.1-T153V), which retains bulk at that site, but reduces polarity. As shown in Fig. 4A , the percent inhibition by 10 µM VU590 of Kir7.1-T153V (98.7±1.5%; n=5) was not statistically significantly different (P>0.05) from that of Kir7.1-T153C (93±5.6%; n=6). To test the role of polarity at position 153, we mutated T153 to serine (Kir7.1-T153S), which retains polarity, but reduces bulk at that site. The T153S mutation rendered the channel non-functional, so it was retested in the M125R background. The resulting channel (Kir7.1-T153S-M125R) was functional and exhibited VU590 sensitivity (80.2±8.28% at 10 µM VU590; IC 50 = 2.9 µM; 95% CI: 2.3 µM-3.5 µM n≥5) between that of Kir7.1-M125R and both Kir7.1-T153C and Kir7.1-T153V (Fig. 4A, B) . These data are consistent with a model in which the constrained polar hydroxyl group of T153 creates a barrier to the deeper VU590 binding site comprised of A150 and E149.
The Kir7.1 homology model shown in Figs. 5A-B predicts that T153 is located approximately 6Å and 8Å away from A150 and E149, respectively. Considering that the smallest dimensions of VU590 along its long axis in either an extended or folded conformation are greater than 8Å (Fig. 5C ), we postulated that VU590 could possibly engage all three residues simultaneously. We tested this hypothesis by evaluating whether or not the T153C mutation could restore normal block to the A150S and E149Q mutants by VU590. As shown in Fig. 5D ,
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T153 is a barrier to the low-affinity ligand VU714, but not the higher-affinity analog ML418
We recently reported the discovery of a Kir7.1 inhibitor, termed VU714 (Fig. 6A) (IC 50~1 .5 µM), which also requires E149 and A150 for optimal inhibitory activity. Interestingly, the T153C mutation also enhances Kir7.1 inhibition by VU714. In the same report we employed medicinal chemistry to optimize the potency and selectivity of VU714, leading to the development of ML418, a 0.31 µM IC 50 Kir7.1 inhibitor (Fig. 6A ) (Swale et al., 2016) . Here, we used these structural analogs to determine if the effects of the T153C mutation were limited to low-affinity ligands, such as VU590 and VU714, or if the mutation could also enhance the inhibitory activity of higher-affinity ligands, such as ML418. As shown in Fig. 6B , the T153C mutation once again increased block of Kir7.1 by VU714. In contrast, however, the T153C mutation had no effect on the sensitivity of Kir7.1 to ML418. These data suggest that the polar side chain of T153 creates an barrier for low-affinity ligands, but not high-affinity ligands, that interact with E149 and A150 in Kir7.1.
Polarity at position 175 reduces VU590 sensitivity of a low-affinity mutant Kir1.1 channel
Because the polar hydroxyl group on T153 reduces Kir7.1 sensitivity to VU590, we postulated that introducing a hydroxyl group at the equivalent position in Kir1.1, by mutating cysteine 175 to threonine (Kir1.1-C175T), would also reduce the sensitivity of Kir1.1 to VU590.
As shown in Fig. 1D , however, Kir1.1 and Kir1.1-C175T were inhibited to a similar degree by VU590. Considering that 1) the Kir7.1-T153C mutation appears to alter sensitivity to low-
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affinity and not high-affinity blockers, and 2) VU590 is a ~0.2 µM inhibitor of Kir1.1, we retested the Kir1.1-C175T mutation in the N171Q background (Kir1.1-C175T-N171Q), which is inhibited by VU590 with 0.7 µM IC 50 . Interestingly, the C175T mutation in Kir1.1-N171Q
background significantly reduced the potency of VU590 for Kir1.1 and shifted the IC 50 value for Kir1.1-N171Q channel almost threefold to ~1.8 µM (Fig. 7B) .
In silico docking of VU590 into Kir1.1 and Kir7.1 homology models
In silico docking calculations were performed in an effort to identify energetically favorable VU590 docking poses in Kir1.1 and Kir7.1. Figure 8 shows the 5 top-scoring conformations of VU590 in the binding pockets of Kir1.1 (Fig. 8A ) and Kir7.1 (Fig. 8B ).
Although the resolution of the models is too low to identify with confidence interactions between VU590 functional groups and amino acid side chains, the conformation of VU590 tends to be different between the two channels. These data are consistent with our structure-function results indicating that the VU590-channel interface is different between Kir1.1 and Kir7.1
Discussion
The major finding of this study is that VU590 blocks Kir1.1 and Kir7.1 at equivalent locations within the membrane pore, but does so through distinct interactions between the ligand and the channel protein. Comparison of the VU590 structure-activity-relationships (SAR) toward Kir1.1 and Kir7.1 (Table 1 ) lends further support to this idea (Lewis et al., 2009; Wright et al., 2015) . For example, migrating the -NO 2 group from the 4-position to the 3-position of the phenyl ring reduces potency toward Kir1.1 by 47-fold, but has no effect on activity toward Kir7.1. Migration of the -NO 2 group to the 2-position abolishes activity toward both channels, however, introduction of -NO 2 groups at the 4-and 2-position is well tolerated by Kir7.1, but not Kir1.1.
Finally, whereas substitution of a 4-SMe group is tolerated in Kir7.1, but not in Kir1.1, a 2-Cl group is tolerated in Kir1.1, but not in Kir7.1 (Table 1 ). The divergent SAR and mutagenesis results are consistent with a model in which VU590 assumes different structural conformations and interacts with unique amino acid side chains when blocking the pores of Kir1.1 and Kir7.1.
The region of the pore near Kir1.1-N171 and Kir7.1-E149/A150 is emerging as a common binding site for structurally diverse small-molecule inhibitors of Kir channels (Swale et al., 2014) . Mutagenesis experiments similar to those performed here have shown that N171 is essential for block of Kir1.1 by VU590, VU591, and Compound A; VU591 also requires V168
for optimal activity, whereas the other two blockers do not (Garcia et al., 2014; Swale et al., 2015) . Residues equivalent to Kir1.1-N171 and Kir7.1-E149 are necessary for block of Kir2. E158) are collectively known as "rectification controllers" due to their important roles in mediating interactions with intracellular polyamines and Mg 2+ underlying inward rectification (Lu and MacKinnon, 1994; Stanfield et al., 1994; Wible et al., 1994) . Given that Kir channels apparently have few "druggable" binding pockets, it is not surprising that some synthetic smallmolecule inhibitors co-opt pore-lining structures that evolved to mediate interactions with natural pore blockers (e.g. polyamines).
Mutation of T153 to cysteine in Kir7.1 reduces VU590 IC 50 from 7 µM to ~1 µM.
Threonine 153 is next to glycine 154 (G154), the so-called "glycine hinge," which is conserved in all Kir channels and is thought to serve as a flexure point in transmembrane domain 2 that enables opening and closing of the helix-bundle gate (Shang and Tucker, 2008) . We therefore considered the possibility that the T153C mutation improved VU590 potency through neighboreffects on the glycine hinge and helix-bundle gate opening, thereby improving access of VU590 to its binding site deeper within the pore. However, we found no difference in VU590 potency between Kir7.1-G154A and the Kir7.1-G154A-T153C double mutant, indicating that the change in potency is not due to indirect effects on the glycine hinge and helix-bundle gate opening.
What could be the physicochemical basis of T153 reducing VU590 block of Kir7.1? We explored this question by comparing the VU590 sensitivity of Kir7.1 channels carrying T153C, T153V, or T153S. Mutation of T153 to cysteine or valine increased VU590 sensitivity to the same extent, whereas mutation to serine led to a partial increase in sensitivity. The side chain of cysteine is slightly less polar than that of threonine, and is able to rotate more freely due to the absence of a -CH3 group. It is conceivable that the -SH group on cysteine rotates out of the pore as VU590 approaches A150 and E149 and thereby minimizes repulsive interactions between while retaining rotamer freedom with the T153S mutation (-OH group) led to a small but statistically significant improvement in VU590 potency, whereas removing side chain polarity and decreasing rotamer freedom with the T153V mutation (two -CH3 groups) increased VU590 sensitivity to a level comparable to that of Kir7.1-T153C. Taken together these observations are consistent with a model in which the -OH group on T153 is constrained by its neighboring -CH3 group to face the pore and undergo repulsive interactions with polar atoms on VU590. Mutations that reduce constrained polarity in the pore at this position thus improve VU590 potency.
Based on this model, we postulated that introducing a constrained -OH group into the equivalent pore location would also reduce Kir1.1's sensitivity to block by VU590. However, replacing cysteine 175 with threonine (Kir1.1-C175T) had no effect on the VU590 potency, leading us to think initially that the mechanism is unique to Kir7.1. We then considered the observations that the T153C mutation improved the activity of the low-affinity blocker VU714, but not the higher-affinity analog ML418. Because VU590 is a high-affinity Kir1.1 blocker (0.2 µM IC 50 ), we re-evaluated the effects of the C175T mutation on Kir1.1 carrying the N171Q mutation, which renders the channel less sensitivity to VU590 (0.7 µM IC 50 ). In the N171Q background, the C175T mutation led to a 3-fold increase in VU590 IC 50 , lending support to the model.
In conclusion, we have identified key residues in the Kir1.1 and Kir7.1 channel pores that are critical for optimal block by VU590. 
